M J Manco-Johnson
Overview
Explore the profile of M J Manco-Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, et al.
J Thromb Haemost
. 2017 Dec;
16(2):253-261.
PMID: 29220876
Summary: Background Human fibrinogen concentrate (HFC) corrects fibrinogen deficiency in congenital a-/hypofibrinogenemia. Objectives To assess pharmacokinetics (PK), effects on thromboelastometry maximum clot firmness (MCF), and safety of a new double...
2.
Manco-Johnson M, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, et al.
J Thromb Haemost
. 2017 Aug;
15(11):2115-2124.
PMID: 28836341
Summary: Background Limited data exist on the impact of prophylaxis on adults with severe hemophilia A and pre-existing joint disease. Objectives To describe 3-year bleeding, joint health and structure, health-related...
3.
Fischer K, Poonnoose P, Dunn A, Babyn P, Manco-Johnson M, David J, et al.
Haemophilia
. 2016 Sep;
23(1):11-24.
PMID: 27633342
Introduction: The implementation of early long-term, regular clotting factor concentrate (CFC) replacement therapy ('prophylaxis') has made it possible to offer boys with haemophilia a near normal life. Many different regimens...
4.
Boylan B, Rice A, Neff A, Manco-Johnson M, Kempton C, Miller C
J Thromb Haemost
. 2016 Aug;
14(10):1931-1940.
PMID: 27501440
Summary: Background Hemophilia B (HB) is an inherited bleeding disorder caused by the absence or dysfunction of coagulation factor IX (FIX). A subset of patients who have HB develop neutralizing...
5.
Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson M
Haemophilia
. 2015 Nov;
22(3):374-80.
PMID: 26582282
Introduction: Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults. Aims/methods: The aim of this...
6.
Antun A, Monahan P, Manco-Johnson M, Callaghan M, Kanin M, Knoll C, et al.
J Thromb Haemost
. 2015 Sep;
13(11):1980-8.
PMID: 26382916
Background: Immune tolerance induction (ITI) in patients with congenital hemophilia A is successful in up to 70%. Although there is growing understanding of predictors of response to ITI, the probability...
7.
Goldenberg N, Abshire T, Blatchford P, Fenton L, Halperin J, Hiatt W, et al.
J Thromb Haemost
. 2015 Jun;
13(9):1597-605.
PMID: 26118944
Background: Randomized controlled trials (RCTs) on pediatric venous thromboembolism (VTE) treatment have been challenged by unsubstantiated design assumptions and/or poor accrual. Pilot/feasibility (P/F) studies are critical to future RCT success....
8.
Nakar C, Manco-Johnson M, Lail A, Donfield S, Maahs J, Chong Y, et al.
Haemophilia
. 2015 Jan;
21(3):365-373.
PMID: 25581638
Current guidelines recommend delaying the start of immune tolerance induction (ITI) until the inhibitor titre is <10 Bethesda units (BU) to improve success. This study was conducted to evaluate ITI...
9.
Blanchette V, Key N, Ljung L, Manco-Johnson M, van den Berg H, Srivastava A
J Thromb Haemost
. 2014 Jul;
12(11):1935-9.
PMID: 25059285
No abstract available.
10.
Soucie J, Miller C, Kelly F, Payne A, Creary M, Bockenstedt P, et al.
Haemophilia
. 2013 Nov;
20(2):230-7.
PMID: 24261612
Inhibitors are a rare but serious complication of treatment of patients with haemophilia. Phase III clinical trials enrol too few patients to adequately assess new product inhibitor risk. This project...